Company continued to see rapid progression and acceleration of enrollment with 180 patients enrolled to date across 46 clinical trial sites, globally
Completion of enrollment of study expected by end of 2023
Company has documented the necessary number of patients reaching the primary efficacy endpoint (overall survival) to conduct pre-planned interim analysis
Topline data from interim analysis expected before year end
https://finance.yahoo.com/news/cns-pharmaceuticals-provides-clinical-trial-120000035.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.